Prospects for therapy of HIV-associated neurologic diseases

Journal of NeuroVirology

Volumn 3, Issue 2, 1997, Pages 89-101

  Sacktor, Ned ^a   McArthur, Justin ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trials; HIV; Neurology; Therapy

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DEOXYGUANOSINE DERIVATIVE; DIDANOSINE; INDINAVIR; MEMANTINE; NEVIRAPINE; PLACEBO; PREDNISONE; SELEGILINE; ZIDOVUDINE;

CONFERENCE PAPER; CYTOMEGALOVIRUS; DEMENTIA; DISEASE ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; NEUROLOGIC DISEASE; NEUROPSYCHOLOGICAL TEST; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030935865     PISSN: 13550284     EISSN: None     Source Type: Journal    
DOI: 10.3109/13550289709015799     Document Type: Conference Paper

References (70)

1. Acker MB (1986). Relationships between test scores and everyday life functioning. In: Uzzell, BP and Gross Y (eds.) Clinical Neuropsychology of Intervention pp. 85-117. Boston: Martinus Nijhoff Publishing.
2. Ad Hoc FDA Dementia Assessment Task Force (1991). Antidementia Drug Assessment Symposium. Neurobiology of Aging 12: 379-382.
3. Adamson DC, Wildemann B, Sasaki M, Glass JD, McArthur JC, Christov VI, Dawson TM, Dawson VL (1996). Immunologic nitric oxide synthase: Elevation in severe AIDS dementia and induction by HIV-1 coat protein, gp41. Science 274: 1917-1921.
4. Albert SM, Marder K. Dooneief G, Bell K, Sano M, Todak G, Stern Y (1995a). Neuropsychologic impairment in early HIV infection. A risk factor for work disability. Arch Neurol 52: 525-530.
5. Albert SM, Todak G, Elkin E, Marder K. Dooneief G, Stern Y (1995b). Time allocation and disability in HIV infection: A correlational study. J Occup Sci 1: 21-30.
6. Bacellar H, Munoz A, Miller EN, Cohen BA, Besley D, Seines OA, Becker JT, McArthur JC (1994). Temporal trends in the incidence of HIV-1 related neurologic diseases: Multicenter AIDS Cohort Study, 1985-1992. Neurology 44: 1892-1900.
7. Barker PB, Lee RR, McArthur JC (1995). AIDS dementia complex: Evaluation with proton MR spectroscopic imaging. Radiology 195: 58-64.
8. Belman AL, Diamond G, Dickson D, Horoupian D, Llena J, Lantos G, Rubinstein A (1988). Pediatric acquired immunodeficiency syndrome. Neurologic syndromes [published erratum appears in Am J Dis Child 1988 May; 142(5):507]. Am J Dis Child 142: 29-35.
9. Benos DJ, Hahn BH, Bubien JK, Ghosh SK, Mashburn NA, Chaikin MA, Shaw GM, Benveniste EN (1994). Envelope glycoprotein gp120 of human immunodeficiency virus type 1 alters ion transport in astrocytes: Implications for AIDS dementia complex. Proc Natl Acad Sci USA 91: 494-498.
10. Bouwman FH, Skolasky R, Hes D, Selnes OA, Glass JD, Nance-Sproson TE, Royal W, Dal Pan GJ, McArthur JC (1996). Rapid progression of HIV-associated dementia: Association with CNS immune activation (Un Pub).
11. Burger DM, Kraayeveld CL, Meenhorst PL, Mulder JW, Hoetelmans RMW, Koks CHW, Beijnen JH (1995). Study on didanosine concentrations in cerebrospinal fluid. Pharmacy World & Science 17: 218-221.
12. Butler KM, Husson RN, Balis RM, Brouwers P, Eddy J, el-Amin D, Gress J, Hawkins M, Jarosinki P, Moss H, Poplack D, Santacroce S, Venzon D, Wiener L, Wolters P, Pizzo PA (1991). Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. N Engl J Med 324: 137-144.
13. Chiesi A, Vella S, Dally LG, Pedersen C, Danner S, Johnson AM, Schwander S, Goebel FD, Glauser M, Antunes F, Lundgren JD (1996). Epidemiology of AIDS dementia complex in Europe. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 11: 39-44.
14. Cinque P, Vago L, Brytting M, Castagna A, Accordini A, Sundqvist V-A, Zanchetta N, D'Arminio Monforte A, Wahren B, Lazzarin A, Linde A (1992). Cytomegalovirus infection of the central nervous system in patients with AIDS: diagnosis by DNA amplification from cerebrospinal fluid. J Infect Dis 166: 1408-1411.
15. Cinque P, Vago L, Dahl H, Brytting M, Terreni MR, Fornara C, Racca S, Castagna A, Monforte AD, Wahren B, Lazzarin A, Linde A (1996). Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases of the central nervous system in HIV-infected patients. AIDS 10: 951-958.
16. Cohen BA, McArthur JC, Grohman S, Patterson B, Glass JD (1993). Neurologic prognosis in CMV polyradiculomyelopathy in AIDS. Neurology 43: 493-499.
17. Cohen RA, O'Donnell BF, Meadows ME, Moonis M, Stone WF, Drachman DA (1995). ERP indicies and neuropsychological performance as predictors of functional outcome in dementia. Journal of Geriatric Psychiatry & Neurology 8: 217-225.
18. Dana Consortium for Treatment of HIV Dementia (1996). Anti-oxidant treatment in HIV dementia. Neuroscience of HIV Infection March 6-9, Paris.
19. Davis KL, Thai LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, Drachman DA, Schneider LS, Whitehouse PJ, Hoover TM, Morris JC, Kawas CH, Knopman DS, Earl NL, Kumar V, Doody RS and The Tacrine Collaborative Study Group (1992). A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 327: 1253-1259.
20. Dewhurst S, Gelbard HA, Fine SM (1996). Neuropathogenesis of AIDS (review). Molecular Medicine Today 2: 16-23.
21. Dieterich DT, Poles MA, Lew EA, Mendez PA, Murphy R, Addessi A, Holbrook JT, Naughton K, Friedberg DN (1993). Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients. J Infect Dis 167: 1184-1188.
22. Fein G, Biggins CA, Mackay S (1995). Delayed latency of the event-related brain potential P3A component in HIV disease. Progressive effects with increasing cognitive impairment. Arch Neurol 52: 1109-1118.
23. Fillet AM, Katlama C, Visse B, Camilleri S, Rogeaux O, Huraux JM (1993). Human CMV infection of the CNS: concordance between PCR detection in CSF and pathological examination. AIDS 7: 1016-1017.
24. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE, Zidovudine Epidemiology Study Group (1992). Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis 166: 1223-1227.
25. Gelbard HA, Dzenko KA, DiLoreto D, del Cerro C, del Cerro M, Epstein LG (1993). Neurotoxic effects of tumor necrosis factor alpha in primary human neuronal cultures are mediated by activation of the glutamate AMPA receptor subtype: Implications for AIDS neuropathogenesis. Dev Neurosci 15: 417-422.
26. Gelbard HA, Nottet HSLM, Swindells S, Jett M, Dzenko KA, Genis P, White R, Wang L, Choi YB, Zhang DX, Lipton SA, Tourtellotte WW, Epstein LG, Gendelman HE (1994). Platelet activating factor. A candidate human immunodeficiency virus type 1-induced neurotoxin. J Virol 68: 4628-4635.
27. Glass JD, Fedor H, Wesselingh SL, McArthur JC (1995). Immunocytochemical quantitation of HIV in the brain: Correlations with HIV-associated dementia. Ann Neurol 38: 755-762.
28. Gozlan J, Salord JM, Roullet E, Baudrimont M, Caburet F, Meyohas MC, Duvivier C, Jacomet C, Petit JC (1992). Rapid detection of cytomegalovirus DNA in cerebrospinal fluid of AIDS patients with neurologic disorders. J Infect Dis 166: 1416-1421.
29. Gozlan J, El Amrani M, Baudrimont M, Costagliola D, Salord JM, Duvivier C, Picard O, Meyohas M, Jacomet C, Schneider-Fauveau V, Petit J-C, Roullet E (1995). A prospective evaluation of clinical criteria and polymerase chain reaction assay of cerebrospinal fluid for the diagnosis of cytomegalovirus-related neurological diseases during AIDS. AIDS 9: 253-260.
30. Graham NMH, Hoover DR, Park LP, Stein DS, Phair JP, Mellors JW, Detels R, Saah AJ, Taylor E, Margolick JB, Markham R, McArthur J, Farzadegan H, Armenian H, Chmeil JS, Cohen B, Wesch J, Wolinsky S, Visscher BR, Fahey JL, Giorgi JV, Dudley J, Lee M, Nishanian P, Rinaldo CR (1996). Survival in HIV-infected patients who have received zidovudine. Comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Ann Intern Med 124: 1031-1038.
31. Griffin DE, Wesselingh SL, McArthur JC (1994). Elevated central nervous system prostaglandins in HIV-associated dementia. Ann Neurol 35: 592-597.
32. Heaton RK, Chelune GJ, Lehman RA (1978). Using neuropsychological and personality tests to assess the likelihood of patient employment. J Nerv Ment Dis 166: 408-416.
33. Heaton RK, Velin RA, McCutchan JA, Gulevich SJ, Atkinson JH, Wallace MR, Godfrey HPD, Kirson DA, Grant I, The HNRC Group (1994). Neuropsychological impairment in human immunodeficiency virus-infection: Implications for employment. Psychosomatic Med 56: 8-17.
34. Hill RD, Backman L, Fratiglioni L (1995). Determinants of functional abilities in dementia. J Am Geriatrics Soc 43: 1092-1097.
35. Huang S, Skolasky R, Dal Pan GJ, Royal W, McArthur JC (1996). Survival prolongation and sympton palliation in HIV seropositive patients with PML treated with alpha interferon (Un Pub).
36. Janssen RS, Nwanyanwu OC, Selik RM, Stehr-Green JK (1992). Epidemiology of human immunodeficiency virus encephalopathy in the United States. Neurology 42: 1472-1476.
37. Kerr DA, Chang CF, Gordon J. Bjornsti MA, Khalili K (1993). Inhibition of human neurotropic virus (JCV) DNA replication in glial cells by camptothecin. Virology 196: 612-618.
38. Koka P, Zack JA, Kitchen S, Peacock W, Fried I, Tran Y, Yashar SS, Merrill JE (1995). Human immunodeficiency virus 1 envelope proteins induce interleukin 1, tumor necrosis factor alpha and nitric oxide in glial cultures derived from fetal, neonatal, and adult human brain. J Exp Med 182: 941-951.
39. Lipton SA, Gendelman HE (1995). Dementia associated with the acquired immunodeficiency syndrome. N Engl J Med 332: 934-940.
40. Magnuson DSK, Knudsen BE, Geiger JD, Brownstone RM, Nath A (1995). Human immunodeficiency virus type 1 Tat activates non-N-methyl-D-aspartate excitatory amino acid receptors and causes neurotoxicity. Ann Neurol 37: 373-380.
41. Maj M, Satz P, Janssen R, Zaudig M, Starace F, D'Elia L, Sughondhabirom B, Mussa M, Naber D, Ndetei D, Schulte G, Sartorius N (1994). WHO Neuropsychiatric AIDS Study, Cross-sectional Phase II. Neuropsychological and neurological findings. Arch Gen Psychiatry 51: 51-61.
42. Manischewitz JF, Quinnan GV, Lane HC, Wittek AE (1990). Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. Antimicrob Agents Chemother 34: 373-375.
43. McArthur JC, Seines OA, Dal Gan GJ, Yost B, Oette D, Gelpke L, Clifford D, Price RW, Wesselingh S, Griffin DE (1994). Phase I/II trial of pentoxifylline in HIV-associated dementia and myelopathy. Neuroscience of HIV Infection: Basic and Clinical Frontiers Vancouver BC Aug 2-5.
44. McArthur JC, Grant I (1996). HIV neurocognitive disorders. Neurological and Neuropsychiatric Manifestations of HIV-1 Infection (In Press).
45. McConnell JR, Swindells S, Ong CS, Gmeiner WH, Chu WK, Brown DK, Gendelman HE (1994). Prospective utility of cerebral proton magnetic resonance spectroscopy in monitoring HIV infection and its associated neurological impairment. AIDS Res Hum Retroviruses 10: 977-982.
46. McKinney RE Jr, Maha MA, Connor EM, Feinberg J, Scott GB, Wulfsohn M, McIntosh K, Borkowsky W, Modlin JF, Weintrub P, O'Donnell K, Gelber RD, Knowlton Rogers G, Nusinoff Lehrman S, Wilfert CM, Protocol 043 Study Group (1991). A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. N Engl J Med 324: 1018-1025.
47. Moore RD, Chaisson RE (1996). Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med 124: 633.
48. Navia BA, Dafni U, Simpson D, Slasor P, McArthur J, Zaborski L, Lipton SA (1996). A Phase I/II trial of nimodipine for the treatment of neurological manifestations associated with HIV infection, including AIDS dementia complex and peripheral neuropathy (Un Pub).
49. Nordic Medical Research Councils HIV Therapy Group (1992). Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. Br Med J 304: 13-17.
50. Persidsky Y, Limoges J, McComb R, Bock P, Baldwin T, Tyor W, Patil A, Nottet HSLM, Epstein L, Gelbard H, Flanagan E, Reinhard J, Pirruccello SJ, Howard E, Gendelman HE (1996). Human immunodeficiency virus encephalitis in SCID mice. Am J Pathol 149: 1027-1053.
51. Philippon V, Vellutini C, Gambarelli D, Harkiss G, Arbuthnott G, Metzger D, Roubin R, Filippi P (1994). The basic domain of the lentiviral Tat protein is responsible for damages in mouse brain: Involvement of cytokines. Virology 205: 519-529.
52. Pizzo PA, Eddy J, Falloon J, Balis FM, Murphy RF, Moss H, Wolters P, Brouwers P, Jarosinski P, Rubin M (1988). Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med 319: 889-896.
53. Portegies P, de Gans J, Lange JM, Derix MM, Speelman H, Bakker M, Danner SA, Goudsmit J (1989). Declining incidence of AIDS dementia complex after introduction of zidovudine treatment [published erratum appears in BMJ 1989 Nov 4;299(6708):1141]. Br Med J 299: 819-821.
54. Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, Unverzagt F (1991). Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology 41: 692-696.
55. Rothlind JC, Bylsma FW, Peyser C, Folstein SE, Brandt J (1993). Cognitive and motor correlates of everyday functioning in early Huntington's disease. J Nerv Ment Dis 181: 194-199.
56. Sardar AM, Bell JE, Reynolds GP (1995). Increased concentrations of the neurotoxin 3-hydroxykynurenine in the frontal cortex of HIV-1-positive patients. J Neurochem 64: 932-935.
57. Sidtis JJ, Gatsonis C, Price RW, Singer EJ, Collier AC, Richman DD, Hirsch MS, Schaerf FW, Fischl MA, Kieburtz K, Simpson D, Koch MA, Feinberg J, Dafni R, AIDS Clinical Trials Group (1993). Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. Ann Neurol 33: 343-349.
58. Sidtis JJ (1994). Evaluation of the AIDS dementia complex in adults. In: Price, RW and Perry, SW, (eds.) HIV, AIDS and the Brain pp. 273-287. New York: Raven Press.
59. Talley AK, Dewhurst S, Perry S, Dollard SC, Gummuluru S, Fine SM, New D, Epstein LG, Gendelman HE, Gelbard HA (1995). Tumor necrosis factor alpha induces apoptosis in human neuronal cells: Protection by the antioxidant N-acetylcysteine and the genes bcl-2 and crm A. Mol Cell Biol 15: 2359-2366.
60. The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders (1996). Clinical confirmation of the American Academy of Neurology algorithm for HIV-1 associated cognitive/motor disorder. Neurology 47: 1247-1253.
61. Toggas SM, Masliah E, Rockenstein EM, Rall GF, Abraham CR, Mucke L (1994). Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 367: 188-193.
62. Tozzi V, Narciso P, Galgani S, Sette P, Balestra P, Gerace C, Pau FM, Pigorini F, Volpini V, Camporiondo MP (1993). Effects of zidovudine in 30 patients with mild to end-stage AIDS dementia complex. AIDS 7: 683-692.
63. Tross S, Price RW, Navia B, Thaler HT, Gold J, Sidtis JJ (1988). Neuropsychololgical characterization of the AIDS dementia complex: a preliminary report. AIDS 2: 81-88.
64. Van Gorp WG, Hinkin C, Satz P, Miller EN, Weisman J, Holston S, Drebing C, Marcotte TD, Dixon W (1993). Subtypes of HIV-related neuropsychological functioning: a cluster analysis approach. Neuropsychology 7: 62-72.
65. Volterra A, Trotti D, Racagni G (1994). Glutamate uptake is inhibited by arachidonic acid and oxygen radicals via two distinct and additive mechanisms. Mol Phar 46: 986-992.
66. Weinberg DV, Murphy R, Naughton K (1994). Combined daily therapy with intravenous ganciclovir and foscarnet for patients with recurrent cytomegalovirus retinitis. Am J Ophthalmol 117: 776-782.
67. Weinshenker BG, Issa M, Baskerville J (1996). Meta-analysis of the placebo-treated groups in clinical trials of progressive MS. Neurology 46: 1613-1619.
68. Wesselingh SL, Power C, Glass J, Tyor WR, McArthur JC, Farber JM, Griffin JW, Griffin DE (1993). Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dementia. Ann Neurol 33: 576-582.
69. Wolf DG, Spector SA (1992). Diagnosis of human cytomegalovirus central nervous system disease in AIDS patients by DNA amplification from cerebrospinal fluid. J Infect Dis 166: 1412-1415.
70. Yeung MC, Pulliam L, Lau AS (1995). The HIV envelope protein gp120 is toxic to human brain-cell cultures through the induction of interleukin-6 and tumor necrosis factor-α. AIDS 9: 137-143.